Asepsis announces the launch of Colistimethate Sodium for Injection in India
Asepsis Pharmaceuticals™ , Inc. announces the product launch of Colistimethate Sodium for Injection in India. This is the first of several product launches Asepsis has planned for India. Colistimethate sodium is used to treat Pseudomonas aeruginosa infections in cystic fibrosis patients, however has recently been indicated and received worldwide notice for use in treating multidrug-resistant infection and is one of the last-resort antibiotics for multidrug-resistant Pseudomonas aeruginosa, Acinetobacter and New Delhi metallo-β-lactamase multidrug-resistant Enterobacteriaceae, also known as the New Deli Superbug.
